This trial is evaluating whether trimethoprim-sulfamethoxazole will improve 1 primary outcome, 14 secondary outcomes, and 2 other outcomes in patients with Pneumocystis. Measurement will happen over the course of 21 days.
This trial requires 300 total participants across 2 different treatment groups
This trial involves 2 different treatments. Trimethoprim-sulfamethoxazole is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"The signs of PCP include fever (72%), weight loss (35%), malaise (22%), and jaundice (5%). Hematological abnormalities and disseminated intravascular coagulation are uncommon. Although pneumocystiasis has no typical histology, the finding of epithelial cells, fibrous stroma, or necrotic nodules suggests infectious pneumonia. The finding of pneumocysts in the liver indicates that PCP has disseminated the infection to the liver, which has not been described previously. Atypical PCP may be misdiagnosed as tuberculosis, cryptococcus, or histoplasmosis." - Anonymous Online Contributor
"The incidence of Pneumocystis pneumonia has been decreasing. Most cases are treated with inhaled and/or intravenous therapy. Pneumocystis Pneumonia is a rare but life-threatening disease. Its prognosis depends upon severity and whether the patient is immunocompromised. The mortality ratio for Pneumocystis pneumonia is approximately 0.3%. Patients who are mechanically ventilated and are receiving high doses of corticosteroids have a greater mortality rate than patients who are not receiving these high doses. Antibiotics, regardless of the route, are highly effective in cases of Pneumocystis Pneumonia." - Anonymous Online Contributor
"In this series, P. aeruginosa was found only in 10% of patients with P. jirovecii infection as a primary diagnosis. The association of P. jirovecii and P. aeruginosa infections was independent of other factors. The possible role of other pathogens remains to be defined." - Anonymous Online Contributor
"Approximately 50 % of people without pre-existing lung disease have signs/symptoms of P. carinii pneumonia (PCP) at some time in their lives. About 80 % of people that do not have this history are diagnosed with PCP as long as they have a positive P. carinii pneumonia IgG serology at some point in their lives. Approximately 60% of people that are diagnosed with PCP do not exhibit symptoms. About 20% of people who are diagnosed with PCP will develop symptomatic disease within three months. PCP can recur in the same person repeatedly over many years. How often PCP occurs in a specific population remains to be determined. P." - Anonymous Online Contributor
"Pneumocystis jiroveci pneumonia after SOT can be managed medically and without any specific antiviral prophylaxis if Pneumocystis jiroveci infection is definitively ruled out, and no identifiable fungal or bacterial pathogens are cultured from samples submitted for further testing." - Anonymous Online Contributor
"Pneumocystis pneumonia is a life-threatening opportunistic infection which most commonly starts when patients are immunocompromised, such as infected by HIV and undergoing chemotherapy. Pneumocystis infections can be life-threatening in the immunocompromised host, and can be lethal in immunocompetent hosts with the compromised immune defenses. \n" - Anonymous Online Contributor
"A recent update to the data for pneumocystis infections demonstrates a general increase in the global incidence of PCP. The underlying causes, patient-related risk factors, and prognosis for patients with PCP has not changed substantially over time. These factors appear to have been largely unchanged over recent years. Further research into the pathogenesis and treatment of PCP is crucial to assure a continued decrease in this disease and its consequences." - Anonymous Online Contributor
"Results from a recent paper provides estimates of the average age of people who get PCP infections and estimates the number of cases, both over time and in different countries. Results from a recent paper also allows an examination of how a change in the age of people at risk may affect the number of cases." - Anonymous Online Contributor
"There were no clinical trials that took place before the trial using trimethoprim-sulfamethoxazole to treat pneumocystis pneumonia. However, there were six studies that showed a benefit in patients who already had pneumocystis pneumonia. However, there were no studies that looked at trimethoprim-sulfamethoxazole in patients with previous pneumocystis infections." - Anonymous Online Contributor
"The primary causes of P. pneumoniae pneumonias relate to patient factors, particularly immunosuppressive state and age. These data may guide the use of specific antibiotics and specific management of patients with P. pneumoniae pneumonias." - Anonymous Online Contributor
"Sulfamethoxazole-trimethoprim was discontinued in the United States because of the development of trimethoprim-sulfamethoxazole resistance. Resistance to sulfamethoxazole-trimethoprim exists in emerging countries, and trimethoprim-sulfamethoxazole is now routinely prescribed in the treatment of tuberculosis. New formulations are under study, such as trimethoprim-nitroso-sulfamethoxazole (TMP/NOX, Dantrolisin, Septron) as salvage therapy for resistant organisms or for prevention of P. aeruginosa infections in immunocompromised or otherwise severely critically ill patients." - Anonymous Online Contributor
"This analysis demonstrates that trimethoprim-sulfamethoxazole is commonly used in combination with other antimicrobial treatments. Further investigation and more rigorous data collection are recommended to increase the validity of this analysis." - Anonymous Online Contributor